StreetInsider.com News Articles

Pyxis Oncology Inc. (PYXS) PT Raised to $8 at H.C. Wainwright

Thu, 10 Sep 2026 06:58:02 -0400

(Updated - September 10, 2026 6:58 AM EDT)

H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Pyxis Oncology Inc. (NASDAQ: PYXS) to $8.00 (from $7.00) while maintaining a Buy rating.

The analyst commented: "On September 9, 2026, Pyxis Oncology reported updated data (cut-off: August 18, 2026) from its ongoing global multicenter Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC). Most patients were in the third line at enrollment (N=33 efficacy evaluable; N=35 safety evaluable), and the enrollment criteria were broad, allowing assessment across key subgroups: HPV-positive

Pyxis Oncology Inc. (PYXS) PT Raised to $8 at H.C. Wainwright

Thu, 10 Sep 2026 06:58:02 -0400

(Updated - September 10, 2026 6:58 AM EDT)

H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Pyxis Oncology Inc. (NASDAQ: PYXS) to $8.00 (from $7.00) while maintaining a Buy rating.

Pyxis Oncology Inc. (PYXS) PT Raised to $19 at Wells Fargo

Thu, 10 Sep 2026 05:18:59 -0400

Wells Fargo analyst Derek Archila raised the price target on Pyxis Oncology Inc. (NASDAQ: PYXS) to $19.00 (from $12.00) while maintaining a Overweight rating.

The analyst comments "We don't think investors fully appreciate MICVO's benefit in 2L+ HNSCC, particularly relative to current SOC. Safety is acceptable and creates a highly favorable benefit/risk profile. We raise our POS and are more convicted in our ~$2B peak est. MICVO delivered robust efficacy met/exceeded our base case (here). The 36% cORR and 6.2 mos mPFS met/exceeded our base case. The 79% 12-mos OS w CI 58%-90% was an upside surprise. Among 5 pts treated

Pyxis Oncology Inc. (PYXS) PT Raised to $19 at Wells Fargo

Thu, 10 Sep 2026 05:18:59 -0400

Wells Fargo analyst Derek Archila raised the price target on Pyxis Oncology Inc. (NASDAQ: PYXS) to $19.00 (from $12.00) while maintaining a Overweight rating.

Pyxis Oncology Inc. (PYXS) PT Raised to $8 at Wedbush

Thu, 10 Sep 2026 03:50:14 -0400

Wedbush analyst Robert Driscoll raised the price target on Pyxis Oncology Inc. (NASDAQ: PYXS) to $8.00 (from $6.00) while maintaining a Outperform rating.

The analyst comments: “PYXS reported updated clinical data from its ongoing Ph 1 monotherapy study evaluating micvotabart pelidotin (MICVO) in patients with 2L+ recurrent/ metastatic head and neck squamous cell carcinoma (R/M HNSCC), focusing on patients treated in the dose expansion subgroup treated at 5.4 mg at or below a dose cap (80 kg and 70 kg body weight for males and females, respectively. In 33 efficacy-evaluable patients, cORR was 36% (n=12/33) with responses occurring rapidly, and 83%

Pyxis Oncology Inc. (PYXS) PT Raised to $8 at Wedbush

Thu, 10 Sep 2026 03:50:14 -0400

Wedbush analyst Robert Driscoll raised the price target on Pyxis Oncology Inc. (NASDAQ: PYXS) to $8.00 (from $6.00) while maintaining a Outperform rating.

Pyxis Oncology reports Phase 1 data for head and neck cancer drug

Wed, 09 Sep 2026 07:00:25 -0400

Pyxis Oncology (Nasdaq: PYXS) reported updated Phase 1 monotherapy data for its antibody-drug conjugate micvotabart pelidotin (MICVO) in patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma, based on an August 18, 2026 data cutoff.

In a population of 33 efficacy-evaluable patients dosed at 5.4 mg/kg intravenously once every three weeks with a dose cap, MICVO showed a 36% confirmed objective response rate and a 94% disease control rate. Median progression-free survival was 6.2 months, and the 12-month overall survival probability was 79%, with median overall survival not yet reached. Clinical activity was observed across HPV status and

Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+

Wed, 09 Sep 2026 07:00:00 -0400

MICVO demonstrated rapid and deep responses, with a 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR), with clinical activity observed across HPV status and prior-treatment subgroups

Substantial survival outcomes include median progression-free survival (mPFS) of 6.2 months and 12-month overall survival (OS) probability of 79%, with clinical activity observed across HPV status and prior-treatment subgroups

No new safety signals observed; tolerability profile expected & consistent with prolonged auristatin exposure; dose capping reduced frequency and severity of adverse events in high body weight patients

MICVO potentially addresses significant unmet need

Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+

Wed, 09 Sep 2026 07:00:00 -0400

MICVO demonstrated rapid and deep responses, with a 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR), with clinical activity observed across HPV status and prior-treatment subgroups

Substantial survival outcomes include median progression-free survival (mPFS) of 6.2 months and 12-month overall survival (OS) probability of 79%, with clinical activity observed across HPV status and prior-treatment subgroups

No new safety signals observed; tolerability profile expected & consistent with prolonged auristatin exposure; dose capping reduced frequency and severity of adverse events in high body weight patients

MICVO potentially addresses significant unmet need

Pyxis Oncology to webcast MICVO cancer drug data on Sept. 9

Tue, 08 Sep 2026 16:01:12 -0400

Pyxis Oncology, Inc. (Nasdaq: PYXS) announced it will host a live webcast on September 9, 2026, at 7:30 a.m. Eastern Time to present updated clinical data from its ongoing Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

According to the company's press release, the presentation will cover the scientific rationale for MICVO, an antibody-drug conjugate (ADC); analyses of patients treated at 5.4 mg/kg intravenously once every three weeks; updated efficacy and safety results from the expansion trial; and next steps in clinical development.

The event will feature

Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell

Tue, 08 Sep 2026 16:01:00 -0400

Event to be webcast live on September 9, 2026 at 7:30 a.m. ET
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it will host a live webcast on September 9, 2026 at 7:30 a.m. Eastern Time to present updated clinical data from its ongoing Phase 1 monotherapy study evaluating micvotabart pelidotin (MICVO) in patients with second-line and beyond (2L+) recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

The presentation will include the scientific rationale for Pyxis Oncology’s novel ADC, MICVO; implications of

Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell

Tue, 08 Sep 2026 16:01:00 -0400

Event to be webcast live on September 9, 2026 at 7:30 a.m. ET
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it will host a live webcast on September 9, 2026 at 7:30 a.m. Eastern Time to present updated clinical data from its ongoing Phase 1 monotherapy study evaluating micvotabart pelidotin (MICVO) in patients with second-line and beyond (2L+) recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

The presentation will include the scientific rationale for Pyxis Oncology’s novel ADC, MICVO; implications of

Pyxis Oncology names Thomas Civik permanent CEO and board chair

Tue, 08 Sep 2026 07:30:39 -0400

Pyxis Oncology, Inc. (Nasdaq: PYXS) has appointed Thomas Civik as Chief Executive Officer and Chairman of the Board, effective September 4, 2026, according to a company statement. Civik had served as Interim Chief Executive Officer since February 2026 and as a board member since 2021.
John Flavin, co-founder and founding Chairman of Pyxis Oncology, will transition to Lead Independent Director and continue serving on the board.
"Over the past several months, Tom has demonstrated the leadership, strategic focus and disciplined execution the Board believes are needed as Pyxis Oncology approaches key clinical milestones for MICVO," Flavin said.
Civik previously served as Chairman of

Pyxis Oncology names Thomas Civik permanent CEO and board chair

Tue, 08 Sep 2026 07:30:39 -0400

Pyxis Oncology, Inc. (Nasdaq: PYXS) has appointed Thomas Civik as Chief Executive Officer and Chairman of the Board, effective September 4, 2026, according to a company statement. Civik had served as Interim Chief Executive Officer since February 2026 and as a board member since 2021.
John Flavin, co-founder and founding Chairman of Pyxis Oncology, will transition to Lead Independent Director and continue serving on the board.
"Over the past several months, Tom has demonstrated the leadership, strategic focus and disciplined execution the Board believes are needed as Pyxis Oncology approaches key clinical milestones for MICVO," Flavin said.
Civik previously served as Chairman of

Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board

Tue, 08 Sep 2026 07:30:00 -0400

John Flavin, Co-Founder and Founding Chairman, to serve as Lead Independent Director of the Board

Leadership transition reflects continued focus on advancing MICVO through key clinical milestones

BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, announced today that its Board of Directors has appointed Thomas Civik as Chief Executive Officer and Chairman of the Board, effective as of September 4, 2026. Mr. Civik has served as Interim Chief Executive Officer since February 2026 and as a member of Pyxis Oncology’s Board of Directors since 2021.

In

Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board

Tue, 08 Sep 2026 07:30:00 -0400

John Flavin, Co-Founder and Founding Chairman, to serve as Lead Independent Director of the Board

Leadership transition reflects continued focus on advancing MICVO through key clinical milestones

BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, announced today that its Board of Directors has appointed Thomas Civik as Chief Executive Officer and Chairman of the Board, effective as of September 4, 2026. Mr. Civik has served as Interim Chief Executive Officer since February 2026 and as a member of Pyxis Oncology’s Board of Directors since 2021.

In

Pyxis Oncology to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 07:30:00 -0400

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Tom Civik, Interim Chief Executive Officer and Director of Pyxis Oncology, will participate in fireside chats at three upcoming conferences.

Wells Fargo 21^st Annual Healthcare Conference in Boston, MA on Thursday, September 10, 2026, at 10:15 a.m. ET.

2026 Cantor Global Healthcare Conference in New York, NY on Friday, September 11, 2026, at 10:55 a.m. ET.

H.C. Wainwright 28^th Annual Global Investment Conference in New York, NY on Monday, September

Pyxis Oncology to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 07:30:00 -0400

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Tom Civik, Interim Chief Executive Officer and Director of Pyxis Oncology, will participate in fireside chats at three upcoming conferences.

Wells Fargo 21^st Annual Healthcare Conference in Boston, MA on Thursday, September 10, 2026, at 10:15 a.m. ET.

2026 Cantor Global Healthcare Conference in New York, NY on Friday, September 11, 2026, at 10:55 a.m. ET.

H.C. Wainwright 28^th Annual Global Investment Conference in New York, NY on Monday, September

Form 424B2 Pyxis Oncology, Inc.

Fri, 28 Aug 2026 07:06:00 -0400
si-local-file:///var/storage/secattach/20260828/26992973.html

Form 424B2 Pyxis Oncology, Inc.

Fri, 28 Aug 2026 07:06:00 -0400
si-local-file:///var/storage/secattach/20260828/26992973.html

Form EFFECT Pyxis Oncology, Inc.

Fri, 28 Aug 2026 06:08:00 -0400
si-local-file:///var/storage/secattach/20260828/26992642.html

Form EFFECT Pyxis Oncology, Inc.

Fri, 28 Aug 2026 06:08:00 -0400
si-local-file:///var/storage/secattach/20260828/26992642.html

Form 4 Pyxis Oncology, Inc. For: Aug 20 Filed by: Dupont Jakob

Thu, 20 Aug 2026 18:19:00 -0400
si-local-file:///var/storage/secattach/20260820/26957374.html

Form 4 Pyxis Oncology, Inc. For: Aug 20 Filed by: Dupont Jakob

Thu, 20 Aug 2026 18:19:00 -0400
si-local-file:///var/storage/secattach/20260820/26957374.html

Pyxis Oncology (PYXS) files for 39.2M share offering by selling stockholders

Thu, 20 Aug 2026 16:31:07 -0400

Pyxis Oncology (NASDAQ: PYXS) filed for up to 39,200,306 share offering by selling stockholders.